Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma

O’Byrne Paul M., Bleecker Eugene R., Bateman Eric D., Busse William W., Woodcock Ashley, Forth Richard, Toler William T., Jacques Loretta, Lötvall Jan

Source: Eur Respir J 2014; 43: 773-782
Journal Issue: March
Disease area: Airway diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
O’Byrne Paul M., Bleecker Eugene R., Bateman Eric D., Busse William W., Woodcock Ashley, Forth Richard, Toler William T., Jacques Loretta, Lötvall Jan. Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma. Eur Respir J 2014; 43: 773-782

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Clinical efficacy of once-daily mometasone furoate in children with persistent asthma switched from treatment with fluticasone propionate
Source: Annual Congress 2011 - Airways disease comorbidities and general aspects
Year: 2011

Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012

Variable lipophilicity of budesonide: Comparison with fluticasone propionate, mometasone furoate, and ciclesonide
Source: Eur Respir J 2003; 22: Suppl. 45, 33s
Year: 2003

Efficacy of the novel inhaled corticosteroid, fluticasone furoate (FF)/long-acting beta2-agonist, vilanterol (VI) combination in reducing COPD exacerbations
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012

Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once daily inhalation as a fixed-dose combination in healthy subjects
Source: International Congress 2019 – Clinical studies of asthma treatments
Year: 2019


Mometasone furoate delivered via Breezhaler and Twisthaler in patients with asthma
Source: International Congress 2019 – Asthma: outcomes of clinical trials and cohorts
Year: 2019


Once-daily, high-dose inhaled fluticasone propionate and salmeterol in patients having moderate asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 125s
Year: 2004

A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD
Source: Eur Respir J 2014; 43: 763-772
Year: 2014



Seasonality of asthma exacerbations: efficacy of fluticasone furoate/vilanterol 100/25µg (FF/VI) vs fluticasone furoate 100µg (FF) alone
Source: International Congress 2017 – Asthma management
Year: 2017


Efficacy and safety of ciclesonide compared with fluticasone propionate or budesonide in adolescent patients with persistent asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 458s
Year: 2007

Once-daily versus twice-daily administration of mometasone furoate dry powder inhaler (MF-DPI) improves lung function in children with asthma previously maintained on inhaled corticosteroids (ICS)
Source: Eur Respir J 2004; 24: Suppl. 48, 164s
Year: 2004

Administration of mometasone furoate once daily in the evening is as effective as mometasone furoate administered twice daily in improving lung function in patients with mild to moderate persistent asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 33s
Year: 2003

Comparison of inhaled ciclesonide, fluticasone propinate and fluticasone propionate + salmeterol in maintaining asthma control
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009

Efficacy and safety of the new beclomethasone dipropionate/formoterol combination vs. fluticasone propionate/salmeterol pMDIs in moderate to severe persistent asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 205s
Year: 2006

Low-dose fluticasone is superior to montelukast in asthma patients
Source: Eur Respir J 2001; 18: Suppl. 33, 262s
Year: 2001

Initial maintenance therapy with fluticasone propionate/ salmeterol combination product provides superior asthma control versus montelukast or fluticasone propionate alone
Source: Eur Respir J 2002; 20: Suppl. 38, 386s
Year: 2002

A superior improvement in lung function in patients with moderate persistent asthma is seen with mometasone furoate 200 μg b.i.d delivered by dry powder inhaler compared with beclomethasone dipropionate 168 μg
Source: Eur Respir J 2001; 18: Suppl. 33, 96s
Year: 2001

The pharmacokinetics of mometasone furoate administered by dry powder inhaler following single and multiple dosing in patients with mild-to-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 96s
Year: 2001

Fluticasone propionate/formoterol fumarate combination therapy has superior efficacy to both fluticasone and formoterol alone
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Year: 2011

Mometasone furoate is a less specific glucocorticoid than fluticasone propionate
Source: Eur Respir J 2002; 20: 1386-1392
Year: 2002